Eclipsebio expands its RNA characterization capabilities with multi-attribute nanopore-based sequencing assay eSTRAND RNA QC™
eSTRAND RNA QC uses direct RNA sequencing to provide multiple critical quality attributes in a single run without requiring reverse transcription or translation.
From promise to proof: Reflections on the 6th mRNA-Based Therapeutics Summit
This year's mRNA-Based Therapeutics Summit proved that RNA is a platform, but drug developers must close analytical gaps to see how their constructs work.
Wacker Biotech and Eclipsebio Announce Strategic Collaboration to Advance RNA Medicine Development and Production
The collaboration will combine Wacker Biotech's large-scale, GMP-compliant manufacturing with Eclipsebio's AI-driven RNA design and sequencing-based characterization for best-in-class end-to-end RNA therapeutic development support.